Fly Intel: Wall Street's top stories for Friday » 16:3004/0304/03/20
MMM, TSLA, BBBY, BAC, JPM, WFC, C, AMZN, WMT, FATE, JNJ, INCY, MIC, AEHR, CHWY
The S&P 500 ended…
Opening call sale in Pfizer struck 7.4% above spot » 13:3004/0304/03/20
Opening call sale in…
Opening call sale in Pfizer struck 7.4% above spot. Shares up 2% today near $33.50 with a large trade on the ISE where a customer sold 10K June 36 calls for 91c to open a new position. Trade details show the sale was made in the form of an electronic auction, with a single buyer paying 2c above the 89c best bid for the order.
Fly Intel: Wall Street's top stories at midday » 12:2804/0304/03/20
MMM, TSLA, JPM, BAC, C, GS, MS, USB, WFC, BBBY, FATE, JNJ, INCY, MIC, AEHR, CHWY
The S&P and Dow are…
Piper Sandler biopharma analysts to hold an analyst/industry conference call » 10:2504/0304/03/20
GILD, MYL, TEVA, AMRX, ABBV, REGN, ALNY, MRNA, INO
Biopharma Analysts Amsellem and Raymond, along with a physician based at the University of Pisa Hospital in Pisa, Italy, who has managed over 100 COVID-19 patients and provides his perspective where New York area could be in 2-3 weeks, on an Analyst/Industry conference call to be held on April 3 at 11 am.
Cantor pharma/biotech analysts to hold analyst/industry conference call » 10:2104/0304/03/20
PFE, LLY, MRK, MRTX, AMGN, JNJ, PHGE
Cantor Fitzgerald Pharmaceuticals Analyst Chen & Kim, Biotech Analysts Young, Kumar & Kluska, along with Dr. Robert Fine from New York-Presbyterian/Columbia University Medical Center review current treatment paradigm for advanced and metastatic colorectal cancer (CRC) and discuss new treatments for CRC on an Analyst/Industry conference call to be held on April 6 at 11 am.
Stifel says Seattle Genetics FDA talks on EV positive, but not surprising » 09:2504/0304/03/20
Stifel analyst Stephen…
Stifel analyst Stephen Willey said Seattle Genetics' disclosure of recent talks with the FDA suggesting a potential pathway to accelerated approval for enfortumab vedotin, or EV, in combination with pembrolizumab in front-line/cisplatin-ineligible mUC patients is "incrementally positive, but not terribly surprising" given the recently-secured Breakthrough Therapy Designation for this indication. He already assumes "a non-insignificant contribution" of EV sales derived from the first-line setting in FY21 and is "inclined to believe some of this upside" is similarly reflected in consensus estimates, said Willey, who keeps a Hold rating on the shares.
Icon signs new service agreement with Pfizer » 09:1404/0304/03/20
ICON (ICLR) announced it…
ICON (ICLR) announced it has signed a three-year agreement with Pfizer (PFE). Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed. The agreement builds on the companies' existing relationship, under which ICON provides global expertise in the planning, execution, management and conduct of clinical trials.
Guggenheim to hold a virtual conference » 09:0704/0304/03/20
Healthcare Talks: Genomic…
Healthcare Talks: Genomic Medicines & Rare Diseases 2020 to be held on April 3.
BioNTech price target raised to $60 from $22 at Canaccord » 08:5404/0304/03/20
Canaccord analyst Arlinda…
Canaccord analyst Arlinda Lee raised the firm's price target on BioNTech (BNTX) to $60 from $22 and keeps a Buy rating on the shares.The analyst noted its COVID-19 vaccine candidate which is partnered with Pfizer (PFE) will enter the clinic in April as the company continues to advance its pipeline.
Novartis says 'deeply dedicated' to global effort to combat COVID-19 » 06:1804/0304/03/20
Novartis said it is…
Novartis said it is "deeply dedicated" to the global effort to combat COVID-19 and "doing our part to support the stability of global healthcare systems. We announced a broad set of measures including the creation of a global fund of $20M to support communities around the world impacted by the COVID-19 pandemic. Novartis also has committed 130 million doses of hydroxychloroquine to support pandemic response. In addition, Novartis joined two key cross-industry research initiatives, the COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard, as well as a COVID-19 directed partnership organized by the Innovative Medicines Initiative. Novartis is separately supporting COVID-19 related clinical investigations of several Novartis medicines. To support access, the Novartis generics and biosimilars division Sandoz became the first company to commit to keeping stable prices for a basket of essential medicines that may help in the treatment of COVID-19."